Navigation Links
Cereset® Announces Mild-Traumatic Brain Injury Focused Clinical Trial Progress

Today Cereset®, the only proven non-invasive technology that helps your brain relax and reset itself, announced the midway point of its randomized research trial for individuals with persisting symptoms following mild-Traumatic Brain Injury (mTBI). The objective of the study is to measure the efficacy of a non-invasive technology which compares tones delivered to a subject’s brain guided by the brain’s own rhythms, versus random unguided tones. The research trial is being conducted in two locations–Uniformed Services University of the Health Sciences (USUHS) in Bethesda, MD; and Womack Army Medical Center (WAMC) in Fort Bragg, NC.

The impressive interim results to date, which are a combination of test and placebo, indicate a possible breakthrough for an intervention treating mTBI. Once completed, the data can be summarized in separate test and placebo results. The final report for results at the trial’s completion will provide definitive measures for the apparent positive changes seen to date.

In the United States, an estimated 190,000 individuals develop persistent symptoms each year following a concussion (mTBI). mTBI has been called the “signature injury” of the wars in Iraq and Afghanistan, with up to 80% of battle injuries attributable to concussive shock waves from an improvised explosive device (IED). Persisting symptoms after mTBI can cause debilitating conditions that may include sleep disturbance, anxiety and/or depression, foggy thinking, headaches, dizziness and behavioral issues. It’s generally accepted that Post-Traumatic Stress Disorder (PTSD) often co-occurs with persisting mTBI.

“Once we realized the prevalence of mTBI amongst servicemen, it became our duty to help these soldiers transition back to a functional and healthy brain potential” said Lee Gerdes, Cereset® Founder and CEO. “Cereset® is designed to alleviate the symptoms and negative effects of brain trauma, so individuals no longer feel stuck in a high-stress neurological environment, long after the battlefield. We’re pleased that the study is yielding positive results and that our technology is aiding the men and women who take on the selfless responsibilities of defending our country to be fully prepared for the next steps in their lives.”

Cereset Research technology has been used in clinical trials at Wake Forest School of Medicine under the direction of Doctor Charles Tegeler, Professor of Neurology. Doctor Tegeler’s findings with PTSD and athletes with persisting-post concussion symptoms were instrumental in securing a $2.8M grant from the Office of the Assistant Secretary of Defense for Health/Traumatic Brain Injury Research Program, under Award No. W81XWH-17-2-0057. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Wake Forest School of Medicine is collaborating in this research through Doctor Tegeler’s involvement as a Co-Investigator. Lee Gerdes, Cereset®/Brain State is the project’s Principal Investigator; Doctor Michael Roy is Principal Investigator at USUHS; and Doctor Wesley Cole is Principal Investigator at WAMC.

For more information on how to participate in the trial please visit and

About Cereset®
Founded in 2003 by Lee Gerdes, Cereset® is the global technology leader in helping your brain relax and reset itself, enabling individuals to achieve higher levels of well-being and balance. The company’s patented BrainEcho® technology uses auditory tones to reflect brain frequencies to create new neural pathways that reset the brain. Cereset® legacy technology has been licensed to over 200 affiliate centers in more than 18 countries to successfully empower more than 150,000 clients in North America and Europe. To schedule an appointment at a Cereset® office, or to learn more, visit and watch

*Disclosure: Please be advised*
(1) "The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702 5014 is the awarding and administering acquisition office" and;
(2) “This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health/Traumatic Brain Injury Research Program under Award No. W81XWH-17-2 0057. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense."
(3) “In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture."
(4) “In the conduct of research utilizing recombinant DNA, the investigator adhered to NIH Guidelines for research involving recombinant DNA molecules."
(5) "In the conduct of research involving hazardous organisms or toxins, the investigator adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories."

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. Personalized Stem Cells, Inc. Announces Clinical Trial Sites Qualified for FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
2. Advancements Announces New Episode Focusing on Innovations in Health, Medicine, and Technology
3. Shoreline Biome Announces International Distribution Partnerships
4. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
5. Trivedi Global, Inc. Announces Research by Alice Branton on the Benefits of Trivedi Effect® Energy Treated Magnesium Gluconate
6. Leak Detection Associates Announces Expansion to Chinese Market – Partnership Agreement Signed With Shanghai Zillion
7. Object Pharma Announces Strategic Acquisition of Metabiologics
8. Milton Hershey School Announces 2019 Alumnus of the Year
9. Leak Detection Associates Announces Release of New Website
10. Gateway Genomics Announces Expanding Office and Research Space to Accommodate Increased Demand for SneakPeek DNA Test
11. Xtalks Announces Its Life Science Webinar Calendar for May 2019
Post Your Comments:
(Date:9/24/2019)... ... September 24, 2019 , ... ... in the area of high-level X-ray methods using synchrotron-produced X-rays to study ... Improved Pharma, will present “Synchrotron X-Ray Diffraction and Pair Distribution Function Analysis ...
(Date:9/24/2019)... (PRWEB) , ... September 24, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... a clinical-stage biopharmaceutical company focused on the development of therapies to treat ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... of Hannah Holscher, PhD, RD, to its Scientific Advisory Board. Dr. Holscher is ... Nutrition and the Division of Nutritional Sciences at the University of Illinois Urbana-Champaign, ...
(Date:9/22/2019)... Ore. (PRWEB) , ... September 20, 2019 , ... ... commercial launch of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . BDNF ... nervous systems. BDNF stimulates the growth and differentiation of new neurons in the ...
Breaking Biology Technology:
(Date:9/30/2019)... ... ... As human induced pluripotent stem cells (hiPSCs) move closer to becoming a ... the human heart, there is an increasing need for stable stem cell lines that ... and easily recorded. A study released today in STEM CELLS details the development of ...
(Date:9/25/2019)... ... September 25, 2019 , ... ... announce it ranked No. 3094 on Inc. Magazine’s annual Inc. 5000 list, the ... revenue growth of 120 percent. Based on this growth, the Houston-based firm also ...
(Date:9/24/2019)... Fla. (PRWEB) , ... September 24, 2019 , ... ... of its technology driven portfolio of 3D porous titanium spinal implants with the ... it’s Ti3D implant offerings while more than tripling the number of cervical and ...
Breaking Biology News(10 mins):